Abstract: Disclosed is a fusion protein of interleukin 2 and an application thereof in the treatment or prevention of inflammatory bowel disease, characterized in that the fusion protein comprises: human interleukin 2 or a variant thereof, and human serum albumin or a variant thereof.

Abstract: An auxiliary device for applying protective film, includes a film application box, one end of the film application box is provided with an accommodation cavity, two symmetrical sliding groove holes are provided on the film application box, each sliding groove hole is provided with a moving block, the front end of each moving block is fixedly installed with an installation box, the rear end of each moving block is fixedly installed with a stop block, the aforementioned accommodation cavity is fixedly installed with two limiting rings, and one side of the aforementioned film application box is provided with protective film.

Abstract: Provided are a fusion protein of interleukin 2 and application thereof in the treatment or prevention of amyotrophic lateral sclerosis (ALS).

Abstract: A fusion protein of interleukin-2 and human serum albumin. By electroporating a plasmid carrying interleukin-2 and human serum albumin fusion gene into a CHO cell, a CHO monoclonal cell line stably and efficiently expressing a human recombinant protein is obtained. The monoclonal cell line can secrete and express a fusion protein of interleukin-2 and human serum albumin. The fusion protein can prolong the plasma half-life of human interleukin-2, and can be used for preparing human interleukin-2 drugs or drugs for treating various diseases such as tumors and immunodeficiency diseases.

Abstract: In some aspects, the present disclosure provides antibodies with high target affinities, as well as compositions comprising the same, and methods of using the same. In some embodiments, antibodies against an IL6 receptor are provided.

Abstract: Provided is an Interleukin-1 Receptor Antagonist (IL-1RN) protein or a variant or analogue thereof, and a fusion protein comprising the following three-parts: the Interleukin-1 Receptor Antagonist protein or a variant or analogue thereof, a domain for half-life extension and an optional tumor necrosis factor receptor 2, and the preparation method and use thereof. The above-mentioned protein mutant and fusion protein have the effects of extended half-life, improved affinity with interleukin-1 receptor and superior biological activity, and find use in the field of treatment and prevention of inflammatory-associated diseases.

Abstract: Provided is a fusion polypeptide as an antagonist for IL4 and IL13. Also provided is a pharmaceutical composition comprising the fusion polypeptide and a pharmaceutically acceptable excipient.

Abstract: In some aspects, the present disclosure provides antibodies with high target affinities, as well as compositions comprising the same, and methods of using the same. In some embodiments, antibodies against an IL6 receptor are provided.

Abstract: Provided are a hydration method for a lyophilized cyclophosphamide composition and a composition and preparation prepared thereby. The hydration method comprises: (a) providing an aqueous solution comprising cyclophosphamide and an optional pharmaceutically acceptable excipient; (b) freeze-drying the solution to obtain a lyophilized composition; and (c) hydrating the lyophilized composition by using liquid water to obtain the product.

Abstract: Provided are novel antibodies with high target affinities against an IL6 receptor. Further provided are compositions containing such antibodies and methods of using the same.

Abstract: In some aspects, the present disclosure provides polypeptides with high binding affinities for ligands, as well as compositions comprising the same, and methods of using the same. In some embodiments, polypeptides having high binding affinity for CD80, CD86, or both are provided.

Abstract: Provided is a process for hydrating Cyclophosphamide freeze-dried compositions and products obtained therefrom.

Abstract: Provided are novel antibodies with high target affinities against an IL6 receptor. Further provided are compositions containing such antibodies and methods of using the same.